Stryker (SYK) recieves FDA clearance for OptaBlate BVN

Stryker (NYSE: SYK), a global leader in medical technologies, announced that its OptaBlate basivertebral nerve ablation system (OptaBlate BVN) received 510(k) clearance from the U.S. Food and Drug Administration. OptaBlate BVNA is used in a targeted minimally invasive procedure providing long-lasting^† vertebrogenic pain relief¹. The addition of the OptaBlate BVN to Stryker's pain portfolio expands its advanced pain therapy solutions for patients and is an intersection of its two core competencies: radiofrequency ablation technology and vertebral access.

"We often see patients with chronic low back pain who have tried multiple treatments—physical therapy, injections, medications—without lasting relief," said Dr. Jad Khalil, Spine Surgeon at Michigan Orthopaedic Surgeons. "BVNA is a minimally invasive and innovative procedure that targets a key source of this pain, particularly in patients with specific MRI findings. Before BVNA, options for lasting relief were limited. For many, it offers meaningful improvement and can help avoid more aggressive treatments like surgery."

Key features of the system include:

• Achieves at least a 1 cm lesion in 7 minutes²
• Steerable, dynamic curved introducer for targeted performance²
• Microinfusion technology, which keeps the zone hydrated, reducing impedance errors and preventing charring²
• 10-gauge access tools

"We have a long history in radiofrequency ablation, and we're relentlessly committed to delivering groundbreaking approaches to protect and promote quality of life," said Kristen Berg, vice president and general manager of Stryker's Interventional Spine business. "Our legacy providing solutions to reduce pain now continues with OptaBlate BVN, addressing the underserved population suffering from chronic vertebrogenic lumbar pain."

Stryker's Interventional Spine business will introduce OptaBlate BVN as part of its pain portfolio at the American Society of Pain & Neuroscience (ASPN) Annual Meeting, July 17-20, in Miami, FL. (Booth #154).

You May Also Be Interested In

• Japan Scraps US Meeting As US Asks For More Defense Spending - FT
• Actuate Therapeutics (ACTU) Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial
• Several Forms Of Generic Ritalin Fail To Work Correctly: Study - Bloomberg